This HTML5 document contains 39 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n11http://linked.opendata.cz/resource/drugbank/drug/DB05197/identifier/chemspider/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n7http://bio2rdf.org/drugbank:
n10http://linked.opendata.cz/resource/drugbank/drug/DB05197/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n12http://linked.opendata.cz/resource/drugbank/drug/DB05197/identifier/pubchem-substance/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/resource/drugbank/drug/DB05197/identifier/drugbank/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB05197
rdf:type
n3:Drug
n3:description
Sofalcone is a mucosal protective agent that has been reported to inhibit growth of Helicobacter pylori. on adherence, production of vacuolating toxin (VT), and induction of interleukin-8 (IL-8) secretion by H. pylori.
n3:generalReferences
# Isomoto H, Furusu H, Ohnita K, Wen CY, Inoue K, Kohno S: Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin. World J Gastroenterol. 2005 Mar 21;11(11):1629-33. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15786539
n3:group
investigational
n3:indication
Investigated for use/treatment in gastroenteritis and ulcers.
owl:sameAs
n7:DB05197
dcterms:title
Sofalcone
adms:identifier
n9:DB05197 n10:5282219 n11:4445402 n12:12012583
n3:mechanismOfAction
Sofalcone has been reported to have an anti-bacterial effect on H. pylori and the inhibitory effects against the pathogenic factor of H. pylori in addition to the mucosal protective effect due to the inhibition of prostaglandins degradation enzyme. Sofalcone has a direct bactericidal effect on H pylori, anti-urease activity and reduces the adhesion of this organism to gastric epithelial cells
n3:IUPAC-Name
n4:271B6516-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B651C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B651B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B6518-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B6519-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B651A-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B6514-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B6512-363D-11E5-9242-09173F13E4C5 n4:271B6515-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B6513-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B6522-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B6523-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B651D-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B651E-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B6520-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B651F-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B6521-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
64506-49-6
n3:Bioavailability
n4:271B6528-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B652A-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B652B-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B6527-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B6526-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B6529-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B6517-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B6524-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B6525-363D-11E5-9242-09173F13E4C5